Plasma estrogen levels, estrogen receptor gene variation, and ischemic arterial disease in postmenopausal women: The Three-City prospective cohort study

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 8, 2014, Pages

  Scarabin Carré, Valérie ^a   Brailly Tabard, Sylvie ^b,c   Ancelin, Marie Laure ^d   Maubaret, Cécilia ^a   Guiochon Mantel, Anne ^b,c   Canonico, Marianne ^c,e   Scarabin, Pierre Yves ^a  

^a CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^b BICÊTRE HOSPITAL   (France)

^c INSERM   (France)

^d UNIV MONTPELLIER   (France)

^e UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CITIES; CORONARY ARTERY DISEASE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; FRANCE; GENOTYPE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTMENOPAUSE;

EID: 84905865038     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-4472     Document Type: Article

References (46)

1. Rosner W, Hankinson SE, Sluss PM, Vesper HW, Wierman ME. Challenges to the measurement of estradiol: an Endocrine Society Position Statement. J Clin Endocrinol Metab. 2013;98:1376-1387.
2. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002;94:606-616.
3. Ravaglia G, Forti P, Maioli F, et al. Endogenous sex hormones as risk factors for dementia in elderly men and women. J Gerontol Series A Biol Sci Med Sci. 2007;62:1035-1041.
4. Carcaillon L, Garcia-Garcia FJ, Tresguerres JAF, Avila GG, Kireev R, Rodriguez-Manas L. Higher levels of endogenous estradiol are associated with frailty in postmenopausal women from the Toledo Study for Healthy Aging. J Clin Endocrinol Metab. 2012;97:2898-2906.
5. MaggioM, Ceda GP, Lauretani F, et al. Relationship between higher estradiol levels and 9-year mortality in older women: the Invecchiare in Chianti study. J Am Geriatr Soc. 2009;57:1810-1815.
6. Rexrode KM, Manson JE, Lee IM, et al. Sex hormone levels and risk of cardiovascular events in postmenopausal women. Circulation. 2003;108:1688-1693.
7. Chen Y, Zeleniuch-Jacquotte A, Arslan AA, Wojcik O, et al. Endogenous hormones and coronary heart disease in postmenopausal women. Atherosclerosis. 2011;216:414-419.
8. Lee JS, Yaffe K, Lui LY, et al. Prospective study of endogenous circulating estradiol and risk of stroke in older women. Arch Neurol. 2010;67:195-201.
9. Scarabin-Carre V, Canonico M, Brailly-Tabard S, et al. High level of plasma estradiol as a new predictor of ischemic arterial disease in older postmenopausal women: the three-city cohort study. J Am Heart Assoc. 2012;1:e001388.
10. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340:1801-1811.
11. Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. Mechanisms of disease: production and actions of estrogens.NEngl JMed. 2002; 346:340-352.
12. Herrington DM, Howard TD, Hawkins GA, et al. Estrogen-receptor polymorphisms and effects of estrogen replacement on highdensity lipoprotein cholesterol in women with coronary disease. N Engl J Med. 2002;346:967-974.
13. Deroo BJ, Korach KS. Estrogen receptors and human disease. J Clin Invest. 2006;116:561-570.
14. Saltiki K, Alevizaki M. Coronary heart disease in postmenopausal women; the role of endogenous estrogens and their receptors. Hormones (Athens, Greece). 2007;6:9-24.
15. Lluis-Ganella C, Lucas G, Subirana I, et al. Qualitative assessment of previous evidence and an updated meta-analysis confirms lack of association between the ESR1 rs2234693 (PvuII) variant and coronary heart disease in men and women. Atherosclerosis. 2009;207: 480-486.
16. Molvarec A, Szeplaki G, Kovacs M, et al. Estrogen receptor α (ESR1) PvuII and XbaI gene polymorphisms in ischemic stroke in a Hungarian population. Clin Chim Acta. 2007;382:100-105.
17. Munshi A, Sharma V, Kaul S, et al. Estrogen receptor α genetic variants and the risk of stroke in a South Indian population from Andhra Pradesh. Clin Chim Acta. 2010;411:1817-1821.
18. Rexrode KM, Ridker PM, Hegener HH, Buring JE, Manson JE, Zee RYL. Polymorphisms and haplotypes of the estrogen receptor-gene (ESR2) and cardiovascular disease in men and women. Clin Chem. 2007;53:1749-1756.
19. Markoula S, Milionis H, Lazaros L, et al. Associations of ESR2 Alul (G/A) polymorphism with ischemic stroke in Caucasians. J Neurol Sci. 2012;316:126-130.
20. Canonico M, Brailly-Tabard S, Gaussem P, et al. Endogenous oestradiol as a positive correlate of plasma fibrinogen among older postmenopausal women: a population-based study (the Three-City cohort study). Clin Endocrinol (Oxf). 2012;77:905-910.
21. Maggio M, Ceda GP, Lauretani F, et al. SHBG, Sex hormones, and inflammatory markers in older women. J Clin Endocrinol Metab. 2011;96:1053-1059.
22. Alperovitch A. Vascular factors and risk of dementia: design of the Three-City study and baseline characteristics of the study population. Neuroepidemiology. 2003;22:316-325.
23. Carcaillon L, Alhenc-Gelas M, Bejot Y, et al. Increased thrombin generation is associated with acute ischemic stroke but not with coronary heart disease in the elderly: the Three-City cohort study. Arterioscl Thromb Vasc Biol. 2011;31:1445-1451.
24. Prentice RL. On the design of synthetic case-control studies. Biometrics. 1986;42:301-310.
25. Wacholder S. Practical considerations in choosing between the casecohort and nested case-control designs. Epidemiology (Cambridge, Mass.) 1991;2:155-158.
26. Ryan J, Carriere I, Carcaillon L, et al. Estrogen receptor polymorphisms and incident dementia: the prospective 3C study. Alzheimers Dement. 2014;10:27-35.
27. Rosenkranz K, Hinney A, Ziegler A, et al. Systematic mutation screening of the estrogen receptor α gene in probands of different weight extremes: identification of several genetic variants. J Clin Endocrinol Metab. 1998;83:4524-4527.
28. Jeng MH, Shupnik MA, Bender TP, Westin EH, et al. Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology. 1998;139:4164-4174.
29. Carcaillon L, Gaussem P, Ducimetiere P, et al. Elevated plasma fibrin D-dimer as a risk factor for vascular dementia: the Three-City cohort study. J Thromb Haemost. 2009;7:1972-1978.
30. Straczek C, Ducimetiere P, Barberger-Gateau P, et al. Higher level of systemic C-reactive protein is independently predictive of coronary heart disease in older community-dwelling adults: the Three- City study. J Am Geriatr Soc. 2010;58:129-135.
31. Tregouet DA, Garelle V. A new JAVA interface implementation of THESIAS: testing haplotype effects in association studies. Bioinformatics (Oxford, England). 2007;23:1038-1039.
32. Barlow WE. Robust variance estimation for the case-cohort design. Biometrics. 1994;50:1064-1072.
33. Barlow WE, Ichikawa L, Rosner D, Izumi S. Analysis of case-cohort designs. J Clin Epidemiol. 1999;52:1165-1172.
34. Korn EL, Graubard BI, Midthune D. Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol. 1997;145:72-80.
35. Schuit SCE, Oei HHS, Witteman JCM, et al. Estrogen receptor α gene polymorphisms and risk of myocardial infarction. JAMA. 2004;291:2969-2977.
36. Lu H, Higashikata T, Inazu A, et al. Association of estrogen receptor-β gene polymorphisms with coronary artery disease in patients with familial hypercholesterolemia. Arterioscl Thromb Vasc Biol. 2002;22:817-823.
37. Matsubara Y, Murata M, Kawano K, et al. Genotype distribution of estrogen receptor polymorphisms in men and postmenopausal women from healthy and coronary populations and its relation to serum lipid levels. Arterioscl Thromb Vasc Biol. 1997;17:3006-3012.
38. Kjaergaard AD, Ellervik C, Tybjaerg-Hansen A, et al. Estrogen receptor α polymorphism and risk of cardiovascular disease, cancer, and hip fracture: cross-sectional, cohort, and case-control studies and a meta-analysis. Circulation. 2007;115:861-871.
39. Rossouw J, Bray P, Liu JM, Kooperberg C, et al. Estrogen receptor polymorphisms and the vascular effects of hormone therapy. Arterioscl Thromb Vasc Biol. 2011;31:464-469.
40. Onland-MoretNC, van GilsCH, RoestM, Grobbee DE, Peeters PH. The estrogen receptor α gene and breast cancer risk (The Netherlands). Cancer Causes Control. 2005;16:1195-1202.
41. Stork S, Bots ML, Grobbee DE, van der Schouw YT. Endogenous sex hormones and C-reactive protein in healthy postmenopausal women. J Intern Med. 2008;264:245-253.
42. Mysliwska J, Rutkowska A, Hak L, Siebert J, Szyndler K, Rachon D. Inflammatory response of coronary artery disease postmenopausal women is associated with the IVS1-397T - C estrogen receptor α polymorphism. Clin Immunol (Orlando, Fla.). 2009;130:355-364.
43. Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005;294: 1799-1809.
44. Herrington DM, Howard TD, Brosnihan KB, et al. Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation. 2002;105:1879-1882.
45. Haiman CA, Dossus L, Setiawan VW, et al. Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Res. 2007;67:1893-1897.
46. Stanczyk FZ, Jurow J, Hsing AW. Limitations of direct immunoassays for measuring circulating estradiol levels in postmenopausal women and men in epidemiologic studies. Cancer Epidemiol Biomarkers Prev. 2010;19:903-906.